<?xml version="1.0" encoding="UTF-8" ?><xml><records><record><database name="Alex2017.enl" path="\\ad.nfit.au.dk\NFDFS\Users\riber\Documents\Webpage\literature\Alex2017.enl">Alex2017.enl</database><source-app name="EndNote" version="18.0">EndNote</source-app><rec-number>8</rec-number><foreign-keys><key app="EN" db-id="efefx5zro22fsmerf23xrde3vda5wttfzx9z">8</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Riber, Camilla Frich</style></author><author><style face="normal" font="default" size="100%">Andersen, Anna Halling Folkmar</style></author><author><style face="normal" font="default" size="100%">Rolskov, Lærke Anegaard</style></author><author><style face="normal" font="default" size="100%">Zuwala, Kaja</style></author><author><style face="normal" font="default" size="100%">Gajda, Paulina</style></author><author><style face="normal" font="default" size="100%">Løvschall, Kaja Borup</style></author><author><style face="normal" font="default" size="100%">Dagnæs-Hansen, Frederik</style></author><author><style face="normal" font="default" size="100%">Banda, Dominic H.</style></author><author><style face="normal" font="default" size="100%">Pietschmann, Thomas</style></author><author><style face="normal" font="default" size="100%">Tolstrup, Martin</style></author><author><style face="normal" font="default" size="100%">Zelikin, Alexander N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Synthetic Polymer with a Structure-Driven Hepatic Deposition and Curative Pharmacological Activity in Hepatic Cells</style></title><secondary-title><style face="normal" font="default" size="100%">ACS Macro Letters</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">ACS Macro Letters</style></full-title></periodical><pages><style face="normal" font="default" size="100%">935-940</style></pages><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">48</style></date></pub-dates></dates><publisher><style face="normal" font="default" size="100%">American Chemical Society</style></publisher><urls><related-urls><url><style face="underline" font="default" size="100%">http://dx.doi.org/10.1021/acsmacrolett.7b00471</style></url></related-urls><pdf-urls><url>internal-pdf://0418116767/PEAA_TOC_small.png</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1021/acsmacrolett.7b00471</style></electronic-resource-num></record><record><database name="Alex2017.enl" path="\\ad.nfit.au.dk\NFDFS\Users\riber\Documents\Webpage\literature\Alex2017.enl">Alex2017.enl</database><source-app name="EndNote" version="18.0">EndNote</source-app><rec-number>7</rec-number><foreign-keys><key app="EN" db-id="efefx5zro22fsmerf23xrde3vda5wttfzx9z">7</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chandrawati, Rona</style></author><author><style face="normal" font="default" size="100%">Olesen, Morten T. J.</style></author><author><style face="normal" font="default" size="100%">Marini, Thatiane C. C.</style></author><author><style face="normal" font="default" size="100%">Bisra, Gurpal</style></author><author><style face="normal" font="default" size="100%">Guex, Anne Géraldine</style></author><author><style face="normal" font="default" size="100%">de Oliveira, Marcelo G.</style></author><author><style face="normal" font="default" size="100%">Zelikin, Alexander N.</style></author><author><style face="normal" font="default" size="100%">Stevens, Molly M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Enzyme Prodrug Therapy Engineered into Electrospun Fibers with Embedded Liposomes for Controlled, Localized Synthesis of Therapeutics</style></title><secondary-title><style face="normal" font="default" size="100%">Advanced Healthcare Materials</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Advanced healthcare materials</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1700385-n/a</style></pages><keywords><keyword><style face="normal" font="default" size="100%">β-glucuronidase</style></keyword><keyword><style face="normal" font="default" size="100%">electrospinning</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme prodrug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">liposomes</style></keyword><keyword><style face="normal" font="default" size="100%">polymer fibers</style></keyword></keywords><dates><pub-dates><date><style face="normal" font="default" size="100%">47</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">2192-2659</style></isbn><urls><related-urls><url><style face="underline" font="default" size="100%">http://dx.doi.org/10.1002/adhm.201700385</style></url></related-urls><pdf-urls><url>internal-pdf://2747046092/electrospin_TOC_small.png</url></pdf-urls></urls><custom7><style face="normal" font="default" size="100%">1700385</style></custom7><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/adhm.201700385</style></electronic-resource-num></record><record><database name="Alex2017.enl" path="\\ad.nfit.au.dk\NFDFS\Users\riber\Documents\Webpage\literature\Alex2017.enl">Alex2017.enl</database><source-app name="EndNote" version="18.0">EndNote</source-app><rec-number>6</rec-number><foreign-keys><key app="EN" db-id="efefx5zro22fsmerf23xrde3vda5wttfzx9z">6</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Walther, Raoul</style></author><author><style face="normal" font="default" size="100%">Rautio, Jarkko</style></author><author><style face="normal" font="default" size="100%">Zelikin, Alexander N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Prodrugs in medicinal chemistry and enzyme prodrug therapies</style></title><secondary-title><style face="normal" font="default" size="100%">Advanced Drug Delivery Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Advanced Drug Delivery Reviews</style></full-title></periodical><keywords><keyword><style face="normal" font="default" size="100%">prodrugs</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme prodrug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">drug delivery</style></keyword><keyword><style face="normal" font="default" size="100%">self immolative linkers</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme</style></keyword></keywords><dates><pub-dates><date><style face="normal" font="default" size="100%">46</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0169-409X</style></isbn><abstract><style face="normal" font="default" size="100%">Prodrugs are cunning derivatives of therapeutic agents designed to improve the pharmacokinetics profile of the drug. Within a prodrug, pharmacological activity of the drug is masked and is recovered within the human body upon bioconversion of the prodrug, a process that is typically mediated by enzymes. This concept is highly successful and a significant fraction of marketed therapeutic formulations is based on prodrugs. An advanced subset of prodrugs can be engineered such as to achieve site-specific bioconversion of the prodrug – to comprise the highly advantageous “enzyme prodrug therapy”, EPT. Design of prodrugs for EPT is similar to the prodrugs in general medicinal use in that the pharmacological activity of the drug is masked, but differs significantly in that site-specific bioconversion is a prime consideration, and the enzymes typically used for EPT are non-mammalian and/or with low systemic abundance in the human body. This review focuses on the design of prodrugs for EPT in terms of the choice of an enzyme and the corresponding prodrug for bioconversion. We also discuss the recent success of “self immolative linkers” which significantly empower and diversify the prodrug design, and present methodologies for the design of prodrugs with extended blood residence time. The review aims to be of specific interest for medicinal chemists, biomedical engineers, and pharmaceutical scientists.</style></abstract><urls><related-urls><url><style face="underline" font="default" size="100%">http://www.sciencedirect.com/science/article/pii/S0169409X17300972</style></url></related-urls><pdf-urls><url>internal-pdf://4035179322/small raoul.png</url></pdf-urls></urls><electronic-resource-num><style face="underline" font="default" size="100%">https://doi.org/10.1016/j.addr.2017.06.013</style></electronic-resource-num></record><record><database name="Alex2017.enl" path="\\ad.nfit.au.dk\NFDFS\Users\riber\Documents\Webpage\literature\Alex2017.enl">Alex2017.enl</database><source-app name="EndNote" version="18.0">EndNote</source-app><rec-number>5</rec-number><foreign-keys><key app="EN" db-id="efefx5zro22fsmerf23xrde3vda5wttfzx9z">5</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Riber, Camilla Frich</style></author><author><style face="normal" font="default" size="100%">Zelikin, Alexander N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Recent advances in macromolecular prodrugs</style></title><secondary-title><style face="normal" font="default" size="100%">Current Opinion in Colloid &amp; Interface Science</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Current Opinion in Colloid &amp; Interface Science</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1-9</style></pages><volume><style face="normal" font="default" size="100%">31</style></volume><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">45</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1359-0294</style></isbn><abstract><style face="normal" font="default" size="100%">Macromolecular prodrugs (MP) are high molar mass conjugates, typically carrying several copies of a drug or a drug combination, designed to optimize delivery of the drug, that is — its pharmacokinetics. From its advent several decades ago, design of MP has undergone significant development and established solid guidelines for engineering successful MP in terms of the choice of the polymer carrier, its molar mass, and the choice of the linkage between the drug and the polymer. This review provides a brief account of the state-of-the-art in the development of MP and details the advantages of these tools of drug delivery. We also identify the challenges that need to be further addressed and offer a view on what is currently being done towards these goals. Specifically, we focus on i) the design of high molar mass, main-chain degradable polymers as drug carriers; ii) drug delivery using endogenous macromolecules such as albumin; iii) the choice of biodegradable linkages for drug delivery, and iv) the emerging interest in delivery of short-lived gasotransmitters. With this analysis and presentation, we aim to spur broader interest into MP to facilitate academic and translational development of MP.</style></abstract><urls><related-urls><url><style face="underline" font="default" size="100%">http://www.sciencedirect.com/science/article/pii/S1359029417300377</style></url></related-urls><pdf-urls><url>internal-pdf://0241335345/MP_small.png</url></pdf-urls></urls><electronic-resource-num><style face="underline" font="default" size="100%">https://doi.org/10.1016/j.cocis.2017.06.002</style></electronic-resource-num></record><record><database name="Alex2017.enl" path="\\ad.nfit.au.dk\NFDFS\Users\riber\Documents\Webpage\literature\Alex2017.enl">Alex2017.enl</database><source-app name="EndNote" version="18.0">EndNote</source-app><rec-number>3</rec-number><foreign-keys><key app="EN" db-id="efefx5zro22fsmerf23xrde3vda5wttfzx9z">3</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Madsen, Mikael</style></author><author><style face="normal" font="default" size="100%">Christensen, Rasmus S.</style></author><author><style face="normal" font="default" size="100%">Krissanaprasit, Abhichart</style></author><author><style face="normal" font="default" size="100%">Bakke, Mette R.</style></author><author><style face="normal" font="default" size="100%">Riber, Camilla F.</style></author><author><style face="normal" font="default" size="100%">Nielsen, Karina S.</style></author><author><style face="normal" font="default" size="100%">Zelikin, Alexander</style></author><author><style face="normal" font="default" size="100%">Gothelf, Kurt Vesterager</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Preparation, single-molecule manipulation and energy transfer investigation of a polyfluorene-graft-DNA polymer</style></title><secondary-title><style face="normal" font="default" size="100%">Chemistry – A European Journal</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Chemistry – A European Journal</style></full-title></periodical><pages><style face="normal" font="default" size="100%">n/a-n/a</style></pages><keywords><keyword><style face="normal" font="default" size="100%">DNA</style></keyword><keyword><style face="normal" font="default" size="100%">polymer</style></keyword><keyword><style face="normal" font="default" size="100%">origami</style></keyword><keyword><style face="normal" font="default" size="100%">self-assembly</style></keyword><keyword><style face="normal" font="default" size="100%">Fluorescence</style></keyword></keywords><dates><pub-dates><date><style face="normal" font="default" size="100%">44</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1521-3765</style></isbn><urls><related-urls><url><style face="underline" font="default" size="100%">http://dx.doi.org/10.1002/chem.201702780</style></url></related-urls><pdf-urls><url>internal-pdf://0013874728/madsen_small.png</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/chem.201702780</style></electronic-resource-num></record><record><database name="Alex2017.enl" path="\\ad.nfit.au.dk\NFDFS\Users\riber\Documents\Webpage\literature\Alex2017.enl">Alex2017.enl</database><source-app name="EndNote" version="18.0">EndNote</source-app><rec-number>2</rec-number><foreign-keys><key app="EN" db-id="efefx5zro22fsmerf23xrde3vda5wttfzx9z">2</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fejerskov, Betina</style></author><author><style face="normal" font="default" size="100%">Jarlstad Olesen, Morten T.</style></author><author><style face="normal" font="default" size="100%">Zelikin, Alexander N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Substrate Mediated Enzyme Prodrug Therapy</style></title><secondary-title><style face="normal" font="default" size="100%">Advanced Drug Delivery Reviews</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Advanced Drug Delivery Reviews</style></full-title></periodical><keywords><keyword><style face="normal" font="default" size="100%">Drug delivery</style></keyword><keyword><style face="normal" font="default" size="100%">enzyme prodrug therapy</style></keyword><keyword><style face="normal" font="default" size="100%">controlled delivery</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">43</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">0169-409X</style></isbn><abstract><style face="normal" font="default" size="100%">Substrate mediated enzyme prodrug therapy (SMEPT) is a biomedical platform developed to perform a localized synthesis of drugs mediated by implantable biomaterials. This approach combines the benefits and at the same time offers to overcome the drawbacks for traditional pill-based drug administration and site-specific, implant mediated drug delivery. Specifically, SMEPT offers the flexibility of delivering multiple drugs – individually as monotherapy, in sequence, or as a combination therapy, all of which is also accomplished in a site-specific manner. This technology is also unique for site-specific synthesis of drugs with short half-life, such as nitric oxide. This review presents historical development of SMEPT from early reports to the most recent examples, and also outlines potential avenues for subsequent development of this platform.</style></abstract><urls><related-urls><url><style face="underline" font="default" size="100%">http://www.sciencedirect.com/science/article/pii/S0169409X17300480</style></url></related-urls><pdf-urls><url>internal-pdf://2663967436/SMEPT_small.png</url></pdf-urls></urls><electronic-resource-num><style face="underline" font="default" size="100%">https://doi.org/10.1016/j.addr.2017.04.013</style></electronic-resource-num></record><record><database name="Alex2017.enl" path="\\ad.nfit.au.dk\NFDFS\Users\riber\Documents\Webpage\literature\Alex2017.enl">Alex2017.enl</database><source-app name="EndNote" version="18.0">EndNote</source-app><rec-number>1</rec-number><foreign-keys><key app="EN" db-id="efefx5zro22fsmerf23xrde3vda5wttfzx9z">1</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Chandrawati, Rona</style></author><author><style face="normal" font="default" size="100%">Chang, Jason Y. H.</style></author><author><style face="normal" font="default" size="100%">Reina-Torres, Ester</style></author><author><style face="normal" font="default" size="100%">Jumeaux, Coline</style></author><author><style face="normal" font="default" size="100%">Sherwood, Joseph M.</style></author><author><style face="normal" font="default" size="100%">Stamer, W. Daniel</style></author><author><style face="normal" font="default" size="100%">Zelikin, Alexander N.</style></author><author><style face="normal" font="default" size="100%">Overby, Darryl R.</style></author><author><style face="normal" font="default" size="100%">Stevens, Molly M.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Localized and Controlled Delivery of Nitric Oxide to the Conventional Outflow Pathway via Enzyme Biocatalysis: Toward Therapy for Glaucoma</style></title><secondary-title><style face="normal" font="default" size="100%">Advanced Materials</style></secondary-title></titles><periodical><full-title><style face="normal" font="default" size="100%">Advanced Materials</style></full-title></periodical><pages><style face="normal" font="default" size="100%">1604932</style></pages><volume><style face="normal" font="default" size="100%">29</style></volume><number><style face="normal" font="default" size="100%">6</style></number><keywords><keyword><style face="normal" font="default" size="100%">β-galactosidase</style></keyword><keyword><style face="normal" font="default" size="100%">glaucoma</style></keyword><keyword><style face="normal" font="default" size="100%">layer-by-layer capsules</style></keyword><keyword><style face="normal" font="default" size="100%">liposomes</style></keyword><keyword><style face="normal" font="default" size="100%">nitric oxide</style></keyword></keywords><dates><year><style face="normal" font="default" size="100%">2017</style></year><pub-dates><date><style face="normal" font="default" size="100%">42</style></date></pub-dates></dates><isbn><style face="normal" font="default" size="100%">1521-4095</style></isbn><urls><related-urls><url><style face="underline" font="default" size="100%">http://dx.doi.org/10.1002/adma.201604932</style></url></related-urls><pdf-urls><url>internal-pdf://Publication_advmat-2456663809/Publication_advmat.png</url></pdf-urls></urls><electronic-resource-num><style face="normal" font="default" size="100%">10.1002/adma.201604932</style></electronic-resource-num></record></records></xml>